Avalon GloboCare
ALBTPhase 1Founded in 2016 and uplisted to Nasdaq in 2018, Avalon GloboCare is advancing precision diagnostics through its proprietary platforms. The company's KetoAir™ breathalyzer is an FDA-registered Class I medical device for ketosis monitoring, while its QTY code platform, developed with MIT, is focused on designing water-soluble cytokine receptors. Avalon operates with approximately 60 full-time employees and is actively expanding its intellectual property portfolio and strategic partnerships.
ALBT · Stock Price
Historical price data
AI Company Overview
Founded in 2016 and uplisted to Nasdaq in 2018, Avalon GloboCare is advancing precision diagnostics through its proprietary platforms. The company's KetoAir™ breathalyzer is an FDA-registered Class I medical device for ketosis monitoring, while its QTY code platform, developed with MIT, is focused on designing water-soluble cytokine receptors. Avalon operates with approximately 60 full-time employees and is actively expanding its intellectual property portfolio and strategic partnerships.
Technology Platform
The QTY code protein design platform, developed with MIT, enables the creation of water-soluble variant cytokine receptors. The KetoAir™ is a breathalyzer system using nanosensor technology for non-invasive ketosis monitoring.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| CD19-CAR-T cells | B-cell Malignancy | Phase 1 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In breath-based diagnostics, Avalon faces competition from other ketone monitors and broader metabolic tracking devices. Its QTY therapeutic platform would compete in the crowded cytokine inhibitor space dominated by large biopharma. Its primary differentiation is its specific MIT-derived protein engineering technology and its FDA-registered diagnostic device.